

COVID VACCINES – PRINCIPAL CLINICAL TRIALS SUMMARY

| Study No. | Study Title | Estimated Study Completion Date |
|------------------|--|--|
| 1 | A Study of Ad26.COVS for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE) | <i>January 2, 2023</i> |
| 2 | A Study of Ad26.COVS for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) | <i>May 31, 2023</i> |
| 3 | A Study of Ad26.COVS in Adults (COVID-19) | <i>February 2, 2024</i> |
| 4 | A Study of Ad26.COVS in Healthy Pregnant Participants (COVID-19) (HORIZON 1) | <i>June 20, 2023</i> |
| 5 | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | <i>October 27, 2022</i> |
| 6 | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants | <i>August 26, 2022</i> |
| 7 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | <i>April 13, 2022</i> |
| 8 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | <i>Nov. 1, 2021</i> |
| 9 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | <i>May 2, 2023</i> |
| 10 | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults | <i>April 2023</i> |
| 11 | Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California | <i>July 30, 2023</i> |
| 12 | Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years | <i>Jan. 24, 2023</i> |
| 13 | Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 in Participants ≥16 Years of Age | <i>August 7, 2022</i> |
| 14 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older | <i>July 25, 2022</i> |
| 15 | Efficacy and Safety of COVID-19 Vaccine in Cancer Patients | <i>Dec. 31, 2022</i> |

| | | |
|----|---|---------------------------------|
| 16 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | <i>February 25, 2023</i> |
| 17 | Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients | <i>February 2022</i> |
| 18 | The Lymphoma and Leukemia Society COVID-19 Registry | <i>February 23, 2031</i> |
| 19 | Yale COVID-19 Recovery Study | <i>May 3, 2022</i> |
| 20 | Host Immune Response to Novel RNA COVID-19 Vaccination | <i>January, 2024</i> |